Extended Data Fig. 3: Change in the size of bladder mass on imaging. | Nature Medicine

Extended Data Fig. 3: Change in the size of bladder mass on imaging.

From: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Extended Data Fig. 3

Imaging occurred at baseline and after completion of treatment prior to planned surgery. All patients were included irrespective if they were fit for surgery. Due to definitions of measurable disease not all bladder tumors were measurable at baseline. RECIST v1.1 was used to define response. A positive change denotes an increase in tumor size over time and conversely a negative change denotes a decrease in tumor size over time. Reference lines have been added for response (-30% reduction in tumor size) and progression (20% increase in tumor size). 58 of the 95 treated patients had sequential imaging and radiologically measurable disease at baseline. Radiological progression = 9/58 = 16% (7–27). Radiological response 13/58 = 22% (13–35). 12 patients exhibited no change in their tumor, were not evaluable at pre-cystectomy scan, handled as <10 mm at baseline, and therefore not included in this plot.

Back to article page